JP2006511603A - Use of decaffeinated coffee bean extract in the preparation of compositions intended to stimulate the sebaceous gland function of the skin by oral administration - Google Patents
Use of decaffeinated coffee bean extract in the preparation of compositions intended to stimulate the sebaceous gland function of the skin by oral administration Download PDFInfo
- Publication number
- JP2006511603A JP2006511603A JP2005502448A JP2005502448A JP2006511603A JP 2006511603 A JP2006511603 A JP 2006511603A JP 2005502448 A JP2005502448 A JP 2005502448A JP 2005502448 A JP2005502448 A JP 2005502448A JP 2006511603 A JP2006511603 A JP 2006511603A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- composition
- skin
- cofia
- oral administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 241000533293 Sesbania emerus Species 0.000 title claims abstract description 37
- 210000001732 sebaceous gland Anatomy 0.000 title claims abstract description 16
- 229940069765 bean extract Drugs 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 206010013786 Dry skin Diseases 0.000 claims abstract description 17
- 230000037336 dry skin Effects 0.000 claims abstract description 17
- 239000002537 cosmetic Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 7
- 239000000284 extract Substances 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- 241000769888 Canephora <angiosperm> Species 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000008247 solid mixture Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 240000007154 Coffea arabica Species 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 230000006870 function Effects 0.000 description 9
- 235000013353 coffee beverage Nutrition 0.000 description 8
- 210000002374 sebum Anatomy 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 6
- 235000021028 berry Nutrition 0.000 description 5
- 230000001713 cholinergic effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 229930003799 tocopherol Natural products 0.000 description 5
- 239000011732 tocopherol Substances 0.000 description 5
- 235000019149 tocopherols Nutrition 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 5
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 4
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 4
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 4
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 4
- 206010040844 Skin exfoliation Diseases 0.000 description 4
- 235000021324 borage oil Nutrition 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 4
- 229940074393 chlorogenic acid Drugs 0.000 description 4
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 4
- 235000001368 chlorogenic acid Nutrition 0.000 description 4
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 229940083466 soybean lecithin Drugs 0.000 description 4
- 235000012424 soybean oil Nutrition 0.000 description 4
- 239000003549 soybean oil Substances 0.000 description 4
- 239000010497 wheat germ oil Substances 0.000 description 4
- 241000186012 Bifidobacterium breve Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 235000007460 Coffea arabica Nutrition 0.000 description 3
- 244000016593 Coffea robusta Species 0.000 description 3
- 235000002187 Coffea robusta Nutrition 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 3
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 3
- 244000046052 Phaseolus vulgaris Species 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- -1 diterpene alcohols Chemical class 0.000 description 3
- 230000003291 dopaminomimetic effect Effects 0.000 description 3
- 235000008524 evening primrose extract Nutrition 0.000 description 3
- 239000010475 evening primrose oil Substances 0.000 description 3
- 229940089020 evening primrose oil Drugs 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 241000723377 Coffea Species 0.000 description 2
- 241001284615 Frangula californica Species 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 241001468157 Lactobacillus johnsonii Species 0.000 description 2
- 241000186605 Lactobacillus paracasei Species 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- 235000004433 Simmondsia californica Nutrition 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 235000021038 drupes Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- VNFYMAPAENTMMO-UHFFFAOYSA-N 5-chloro-2-methylquinoline Chemical compound ClC1=CC=CC2=NC(C)=CC=C21 VNFYMAPAENTMMO-UHFFFAOYSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001134772 Bifidobacterium pseudocatenulatum Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- JEKMKNDURXDJAD-UHFFFAOYSA-N Kahweol Natural products C1CC2(CC3(CO)O)CC3CCC2C2(C)C1C(C=CO1)=C1C=C2 JEKMKNDURXDJAD-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229940008075 allyl sulfide Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000040 apocrine gland Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010473 blackcurrant seed oil Substances 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000000804 eccrine gland Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000010647 garlic oil Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- JEKMKNDURXDJAD-HWUKTEKMSA-N kahweol Chemical compound C([C@@H]1C[C@]2(C[C@@]1(CO)O)CC1)C[C@H]2[C@@]2(C)[C@H]1C(C=CO1)=C1C=C2 JEKMKNDURXDJAD-HWUKTEKMSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 150000003577 thiophenes Chemical class 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000004563 wettable powder Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Abstract
本発明は、特に乾燥肌に関連した疾患を直すために、皮膚の皮脂腺機能を刺激することを意図し経口投与用に処方された組成物の調製において、脱カフェインされたコーヒー豆抽出物を使用することに関する。また本発明は、特に皮膚の皮脂腺機能を刺激するために、経口経路により投与されることを意図した化粧品用、栄養又は製薬用組成物に関する。さらに本発明は、乾燥肌を処置するための美容方法に関する。The present invention relates to decaffeinated coffee bean extract in the preparation of a composition formulated for oral administration intended to stimulate sebaceous gland function of the skin, in particular to correct diseases associated with dry skin. About using. The invention also relates to cosmetic, nutritional or pharmaceutical compositions intended to be administered by the oral route, in particular to stimulate the sebaceous gland function of the skin. The present invention further relates to a cosmetic method for treating dry skin.
Description
本発明は、皮膚の皮脂腺機能を刺激することを意図し、特に乾燥肌に関連した疾患を直すことを意図し、経口投与用に処方される組成物の調製に、脱カフェインされたコーヒー豆抽出物を使用することに関する。また本発明は、特に、皮膚の皮脂腺機能を刺激するために、経口経路により投与されることを意図した化粧品用、栄養又は製薬用組成物に関する。さらに本発明は、乾燥肌を処置するための美容方法に関する。 The present invention is intended to stimulate the sebaceous gland function of the skin, and in particular to ameliorate diseases associated with dry skin, in the preparation of a composition formulated for oral administration. It relates to using the extract. The invention also relates to a cosmetic, nutritional or pharmaceutical composition intended to be administered by the oral route, in particular to stimulate the sebaceous gland function of the skin. The present invention further relates to a cosmetic method for treating dry skin.
脂漏分泌過少性(oligoseborrheic)の乾燥肌は、皮脂の分泌及び排出が不十分であることにより特徴付けられる。通常、額で測定した皮脂の濃度が100μg/cm2より少ないことが、このような乾燥肌の特徴であると考えられている。
多くの場合、乾燥肌には、落屑欠陥、くすんだ肌色、弛緩した質感の皮膚が伴う。微炎症性症候、特に皮膚炎は、乾燥肌の場合により一層頻繁に出現する。
通常、乾燥肌の患者は、例えば痙攣性単収縮のような不快な感覚を顔に感じる。
Dry skin with oligoseborrheic is characterized by insufficient sebum secretion and excretion. Usually, it is considered that the concentration of sebum measured with a forehead is less than 100 μg / cm 2 is a characteristic of such dry skin.
In many cases, dry skin is accompanied by desquamation defects, dull skin color, and loose textured skin. Microinflammatory symptoms, particularly dermatitis, appear more frequently in dry skin.
Usually, patients with dry skin feel an unpleasant sensation on their face, for example, convulsive twitches.
経時的加齢には、通常、皮脂腺付属器の機能の喪失が付随するために、これらの疾患の全ては年齢と共に進行する。
他方、正常に脂性の肌は、乾燥肌と比較して、加齢時に改善された状況を示すことが、通常認識されている。この効果は、ビタミンEが皮脂腺経路によって排出されるという事実によるかもしれない(Thieleら, J. Invest. Dermatol. 1999;113;1006-10)。
All of these diseases progress with age, because aging is usually accompanied by a loss of sebaceous appendage function.
On the other hand, it is usually recognized that normally oily skin exhibits an improved situation at aging compared to dry skin. This effect may be due to the fact that vitamin E is excreted by the sebaceous gland pathway (Thiele et al., J. Invest. Dermatol. 1999; 113; 1006-10).
皮脂は、毛嚢脂腺単位の付属器を構成する皮脂腺の天然産物である。汗と共に、エクリン又はアポクリン腺により生成され、表皮の天然の水和剤を構成する。
皮脂腺分泌は、神経由来の種々の求心性の制御下にある。Cartlidgeら(Br. J. Dermatol-1972;86(1), 61-63)は、脂漏症におけるコリン作動系(パラ-リンパ腺)の調節性役割について定めている。さらに、ドーパミン作動系は、パーキンソン症候群の場合におけるように、それが不安定である場合に、L-DOPAにより修正可能な高脂漏症に至ることが知られている(JC Villaresら, Acta Neurol Scand, 80(1), 5Z-63)。またコリン作動系は、ムスカリン性レセプターサブタイプの中間物を介して、ドーパミンの放出に拮抗することも知られている(Pharmacologie, M. Schorderetら, p71, Ed. Frison-Roche, ISBN 2-05-100910-4)。
よって、ドーパミン作動系の活性化及び/又はコリン作動系の阻害(ムスカリン性レセプターを介する)により、皮脂の排出及び/又は脂質生合成の減少に至るかもしれない。
Sebum is a natural product of sebaceous glands that make up the appendage of the follicular sebaceous unit. Along with sweat, it is produced by the eccrine or apocrine glands and constitutes the natural wettable powder of the epidermis.
Sebaceous gland secretion is under the control of various afferents derived from nerves. Cartlidge et al. (Br. J. Dermatol-1972; 86 (1), 61-63) define the regulatory role of the cholinergic system (para-lymph gland) in seborrhea. Furthermore, the dopaminergic system is known to lead to hyperlipidemia that can be corrected by L-DOPA when it is unstable, as in Parkinson's syndrome (JC Villares et al., Acta Neurol Scand, 80 (1), 5Z-63). The cholinergic system is also known to antagonize dopamine release through intermediates of muscarinic receptor subtypes (Pharmacologie, M. Schorderet et al., P71, Ed. Frison-Roche, ISBN 2-05). -100910-4).
Thus, activation of the dopaminergic system and / or inhibition of the cholinergic system (via muscarinic receptors) may lead to decreased sebum excretion and / or lipid biosynthesis.
他方、ドーパミン作動刺激の制限及び/又はコリン作動系の活性化(ムスカリン性レセプターを介する)により、皮脂の分泌及び/又は生成の増加に至るかもしれない。脱カフェインされた又は脱カフェインされていないコーヒー豆のアルコール画分に、ムスカリン型のコリン様作動活性が見出されている(SY Tse, J. Pharm Sci., 1991, 80(7), 665-669、及びSY Tse, J. Pharm Sci., 1992, 81(7), 449-452)。 On the other hand, limiting dopaminergic stimulation and / or activation of the cholinergic system (via muscarinic receptors) may lead to increased sebum secretion and / or production. Muscarinic cholinergic activity has been found in the alcohol fraction of decaffeinated and non-decaffeinated coffee beans (SY Tse, J. Pharm Sci., 1991, 80 (7), 665-669, and SY Tse, J. Pharm Sci., 1992, 81 (7), 449-452).
本発明は、脱カフェインされたコーヒー豆の抽出物を含有する経口投与用の組成物が、皮膚の皮脂腺機能の刺激に対して有益な効果を有し得るという事実を実証したことからなされた。
コーヒーの木は、縁部が滑らかで、多年生であり、革質で光沢のある葉(10−15x4−6cm)を有する小さな木である。白色で芳香性の花が、葉腋において、渦巻き状に群れをなしている。果実は緑の核果であるが、これは成熟すると赤くなり、通常、それらの平面を通って連続している、2つの平面凸状ベリーを含む。2つの種のみがコーヒーの市場で不可欠品として供給されているが(コフィア属アラビカ種及びコフィア属カネフォーラ種)、多数の種のコーヒーの木が東アフリカの熱帯林に野生状態で存在している。
ベリーは、長軸方向の溝部、臍が横断する腹面が平らで、背面が凸状の卵形(10−15x6−8mm)をしている。硬くで緑がかっており、無臭である。緑のコーヒー粉末の顕微鏡検査によれば、外皮及び胚乳細胞から誘導された紡錘状繊維が明らかであり:多角形で、それらの壁部は真珠層で、ビーズ状の構造の不規則な厚みのものであり;それらは油滴を含む。
The present invention was made from demonstrating the fact that a composition for oral administration containing an extract of decaffeinated coffee beans can have a beneficial effect on the stimulation of the sebaceous gland function of the skin. .
The coffee tree is a small tree with smooth edges, perennial, leathery and shiny leaves (10-15x4-6 cm). White and aromatic flowers swirl in the leaf buds. The fruit is a green drupe, which turns red when mature and usually contains two planar convex berries that are continuous through their planes. Although only two species are supplied as an integral part of the coffee market (Kofia arabica and Coffea canephora), many types of coffee trees exist wild in tropical forests of East Africa .
The berry has an oval shape (10-15 × 6-8 mm) in which the groove in the longitudinal direction, the abdominal surface across the umbilicus is flat, and the back surface is convex. Hard, greenish and odorless. Microscopic examination of the green coffee powder reveals spindle-like fibers derived from the rind and endosperm cells: polygons, their walls are nacreous, with irregular thickness of beaded structure They contain oil droplets.
コーヒー「豆」は、コーヒー「チェリー」、すなわち核果から出発して、湿潤経路(発酵、洗浄)又は乾燥経路(乾燥、続いて機械的剥皮)により得られる。赤い外果皮及び肉厚の中果皮を取り除いて、果肉まで減じせしめ;コーヒー「外皮」に至らしめる。皮剥(木化した内果皮の除去)の後に、コーヒー「ベリー」(又は豆)が得られる。
緑のコーヒーベリーの乾燥重量の50%以上は炭水化物、特に多糖類である。タンパク質は、この重量の10〜12%、脂質は10〜18%である。粗脂質の不鹸化画分はかなり(10%以上)であり:さらにステロール類、炭化水素、トコフェロール類、ジテルペン性アルコール(カフェストール、カーウェオール(kahweol)及びカウラン酸(kauranic)誘導体)が、遊離の状態、特に脂肪酸エステルの状態で存在していることが観察されている。コーヒーベリーは、約5%のフェノール酸;キナ酸、コーヒー酸、クロロゲン酸を含有している。カフェイン含有量は可変であり、ある種のカネフォーラ種(ロブスタ変種)では、0.6〜2%、また3%以上である。
The coffee “beans” are obtained from the coffee “cherry”, ie drupe, by the wet route (fermentation, washing) or the dry route (drying followed by mechanical peeling). Remove the red rind and fleshy mesocarp to reduce to flesh; lead to coffee “rind”. After skinning (removal of wooded endocarp), coffee “berries” (or beans) are obtained.
More than 50% of the dry weight of green coffee berries is carbohydrates, especially polysaccharides. Protein is 10-12% of this weight and lipid is 10-18%. The unsaponifiable fraction of the crude lipids is considerable (over 10%): in addition sterols, hydrocarbons, tocopherols, diterpene alcohols (cafe stall, kahweol and kauranic derivatives) It has been observed that it exists in a free state, particularly in the fatty acid ester state. Coffee berry contains about 5% phenolic acid; quinic acid, caffeic acid, chlorogenic acid. The caffeine content is variable and is 0.6-2% and more than 3% for certain canephora species (Robusta varieties).
焙煎時、ベリーの組成とテクスチャーはかなり変化する。水分含有量が減少し、ベリーが膨張し、多糖類が非常に分解し(特に可溶性生成物を生成)、色素が形成され(重縮合したフラン類)、極めて複雑なフレーバーが発生する(数百の化合物:アルコール類、フェノール類、アルデヒド類、フラン及びピロール誘導体、炭化水素、チオフェン類等)。 During roasting, the composition and texture of the berries change considerably. Reduced water content, berries swell, polysaccharides break down very much (especially producing soluble products), pigments are formed (polycondensed furans) and extremely complex flavors are generated (several hundreds) Compounds: alcohols, phenols, aldehydes, furan and pyrrole derivatives, hydrocarbons, thiophenes, etc.).
本出願人が知る限り、脱カフェインされたコーヒー豆の抽出物が、皮膚の皮脂腺機能の刺激を意図し、特に乾燥肌を処置することを意図し、経口投与用に処方された組成物の調製に使用されることは、決して示唆されていない。
よって、本発明の目的は、皮膚の皮脂腺機能を刺激することを意図した組成物の調製における、脱カフェインされたコーヒー豆の抽出物の使用にあり、該組成物は経口投与用に処方されている。
To the best of Applicant's knowledge, decaffeinated coffee bean extract is intended for stimulation of sebaceous gland function in the skin, especially for treating dry skin, and for compositions formulated for oral administration. It is never suggested to be used for preparation.
Thus, an object of the present invention is the use of an extract of decaffeinated coffee beans in the preparation of a composition intended to stimulate the sebaceous gland function of the skin, which composition is formulated for oral administration. ing.
以下の記載において、「コーヒー豆」とは、コーヒー「チェリー」から出発して、湿潤経路(発酵、洗浄)又は乾燥経路(乾燥後に機械的剥皮)により、上述した皮剥の後に得られる豆を意味すると理解されなくてはならない。
「抽出物」とは、粗生成物、この例では、焙煎された又は焙煎されていない脱カフェインされたコーヒー豆の、アルコール又は水性-アルコール抽出から出発して得られるあらゆる化合物を意味するものと理解されなくてはならない。
皮膚による皮脂の生成は、例えばロレアル社の仏国特許第2368708号又は仏国特許第2404845号に記載されている、いわゆる標準的な皮脂測定(sebumetric)法に従い、皮脂の量を測定することにより決定することができる。
「皮膚の皮脂腺機能の刺激」とは、皮膚における皮脂の量を有意に刺激することを意味する。
In the following description, “coffee bean” means a bean obtained after the above-mentioned peeling, starting from the coffee “cherry”, by the wet route (fermentation, washing) or the dry route (mechanical peeling after drying). Then it must be understood.
“Extract” means any compound obtained from alcohol or aqueous-alcohol extraction of a crude product, in this example roasted or non-roasted decaffeinated coffee beans. It must be understood to be.
The production of sebum by the skin is carried out by measuring the amount of sebum according to the so-called standard sebumetric method described in French Patent No. 2368708 or French Patent No. 2404845 of L'Oreal, for example. Can be determined.
“Stimulation of sebaceous gland function in the skin” means that the amount of sebum in the skin is significantly stimulated.
本組成物に使用されるコーヒー豆の抽出物を調製するために選択されるコーヒーの木の種は、有利にはコフィア(Coffea)属の種から選択される。
特定の実施態様では、抽出物は、コフィア属アラビカ種(Coffea arabica)、コフィア属ロブスタ種(Coffea robusta)、コフィア属カネフォーラ種(Coffea canephora)、又はコフィア属リベリカ種(Coffea iberica)の種から選択されるコーヒー豆から得られる。抽出物は、焙煎されたコーヒー豆から出発して得てもよい。焙煎されていないコーヒー豆からも得ることができる。
本発明における使用のためには、コーヒー豆の抽出物は脱カフェインされる。
特に、コーヒー豆の抽出物は、コーヒー豆の水性-アルコール又はアルコール抽出、好ましくはメタノール、エタノール又はプロパノールの補助での抽出により得ることができる。好ましくは、無極性溶媒により抽出可能なコーヒー豆の画分を含まない。
脱カフェインされたコーヒーの抽出物の調製方法は、特にS.Y.H. Tse(上記を参照)、及び以下に付与する実施例に記載する。
The coffee tree species selected to prepare the coffee bean extract used in the present composition is advantageously selected from the species of the genus Coffea.
In certain embodiments, the extract is selected from species of Coffea arabica, Coffea robusta, Coffea canephora, or Coffea iberica Obtained from coffee beans. The extract may be obtained starting from roasted coffee beans. It can also be obtained from unroasted coffee beans.
For use in the present invention, the coffee bean extract is decaffeinated.
In particular, coffee bean extracts can be obtained by aqueous-alcohol or alcohol extraction of coffee beans, preferably extraction with the aid of methanol, ethanol or propanol. Preferably, it does not contain a coffee bean fraction that can be extracted with a non-polar solvent.
Methods for the preparation of decaffeinated coffee extracts are described in particular in SYH Tse (see above) and in the examples given below.
また本発明は、皮膚の皮脂腺機能を刺激することを意図した、脱カフェインされたコーヒー豆の抽出物を含有し、経口投与に適した化粧品用、栄養又は製薬用組成物に関する。特に本発明の組成物は、乾燥肌又は皮膚加齢の処置及び/又は防止を意図している。もちろん、組成物における脱カフェインされたコーヒー豆の抽出物の割合は、皮膚の皮脂腺機能の所望する刺激度合いに応じて、また組成物の投与方式に応じて決定することができる。 The invention also relates to a cosmetic, nutritional or pharmaceutical composition suitable for oral administration, containing an extract of decaffeinated coffee beans intended to stimulate the sebaceous gland function of the skin. In particular, the compositions according to the invention are intended for the treatment and / or prevention of dry skin or skin aging. Of course, the proportion of decaffeinated coffee bean extract in the composition can be determined according to the desired degree of stimulation of the sebaceous gland function of the skin and depending on the mode of administration of the composition.
経口経路により投与されることを意図した組成物は、この投与方式に適した任意のガレノス形態、例えば分割又は非分割錠剤、顆粒、カプセル、ゼラチンカプセル、溶液、懸濁液、又は適切な割形剤を含有する溶液の形態で入手可能である。
組成物は、任意の食品又は製薬品又は経口適用用の化粧品であってよい。食品又は製薬用担体の例は、ミルク、ヨーグルト、カード、チーズ、発酵ミルク、ミルクベースの発酵品、アイスクリーム、発酵した穀物製品、ミルクベースのパウダー、特殊調製粉乳、又はペットフード、又は錠剤、液状の細菌懸濁液、乾燥した経口用サプリメント、湿潤した経口用サプリメント、乾燥したチューブフィーディング又は湿潤したチューブフィーディングである。
Compositions intended to be administered by the oral route may be in any galenic form suitable for this mode of administration, such as divided or undivided tablets, granules, capsules, gelatin capsules, solutions, suspensions, or suitable splits. It is available in the form of a solution containing the agent.
The composition may be any food or pharmaceutical or cosmetic product for oral application. Examples of food or pharmaceutical carriers are milk, yogurt, curd, cheese, fermented milk, milk-based fermented products, ice cream, fermented cereal products, milk-based powder, special formula powder, or pet food, or tablets, Liquid bacterial suspensions, dry oral supplements, wet oral supplements, dry tube feeding or wet tube feeding.
好ましくは、本発明の組成物は、固形組成物、錠剤、顆粒、カプセル、ゼラチンカプセル型の形態で提供される、上述した脱カフェインされたコーヒー豆の抽出物、及び経口投与に適した少なくとも一のアジュバントを含有する栄養サプリメントである。
この点において、経口用組成物、特に食餌用サプリメントのアジュバントは、専門家に知られている。その中でも、純粋に例示目的として、潤滑剤、例えばステアリン酸マグネシウム、瞬時に可溶化させる製品、ゲル化剤、増粘剤、保湿剤、脂肪及び/又は水性化合物、防腐剤、テクスチャー剤、フレーバー及び/又はコーティング剤、抗酸化剤、及び着色物質で、通常食品に使用されているものを挙げることができる。
Preferably, the composition of the present invention is provided in the form of a solid composition, tablet, granule, capsule, gelatin capsule form, and the decaffeinated coffee bean extract described above, and at least suitable for oral administration. A nutritional supplement containing one adjuvant.
In this respect, adjuvants for oral compositions, in particular dietary supplements, are known to the expert. Among them, purely for illustrative purposes, lubricants such as magnesium stearate, instantly solubilized products, gelling agents, thickeners, humectants, fats and / or aqueous compounds, preservatives, texturing agents, flavors and Examples of coating agents, antioxidants, and coloring substances that are usually used in foods can be given.
さらに、本発明の組成物は、脂質、ポリフェノール、タウリン、プロバイオティクス微生物、ビタミン類、及び/又は少数元素を含有していてもよい。プロバイオティクスが使用される場合、それらは生きている形態、半活性又は脱活性形態、例えば凍結乾燥パウダーとして含まれていてよい。また、微生物の培養上清も、組成物に含まれてよい。それらは乳酸菌、特に乳酸桿菌及び/又はビフィズス菌からなる群から選択されてよく、好ましくはLactobacillus johnsonii、Lactobacillus reuteri、Lactobacillus rhamnosus、Lactobacillus paracasei、Lactobacillus casei、Bifidobactedum bifidum、Bifidobacterium breve、Bifidobacterium animalis、Bifidobacterium infantis、Bifidobacterium dolescentis及びBifidobacterium pseudocatenulatumからなる群から選択される。最も好ましい実施態様では、使用される菌株は、パスツール協会にて、ブダペスト条約下、1992年6月30日に寄託され、寄託番号CNCM I-1225を受けているLactobacillus johnsonii(La1)、又はパスツール協会にて、ブダペスト条約下、1999年1月12日に寄託され、寄託番号CNCM I-2116を受けているLactobacillus paracasei(ST11)である。例えば次の化合物:亜鉛、及び硫酸亜鉛及びグルカン酸亜鉛を含むその塩、ビタミンB5、B6、B8、C、E又はPP、β-カロテン及びカロテノイド類、ニンニクの抽出物、特に硫化アリル又はニンニク油の形態のもの、セレニウム、クルクミン、クルクミノイド類、ナイアシン、紫根酸、及びアデノシンを単独で又は組合せて使用してもよい。専門家であれば、このような活性化合物を選択するであろうし、可能であれば、関心ある所望の活性が阻害又は減退されることを防止することにより、本発明の目的である組成物に予期される効果を改善するような形でそれらを組合せるであろうと理解される。
経口投与を意図した組成物は、脱カフェインされたコーヒー豆の抽出物を、組成物の重量に対して0.1%〜80%、好ましくは組成物の重量に対して1%〜50%の範囲の量で含有している。
Furthermore, the composition of the present invention may contain lipids, polyphenols, taurine, probiotic microorganisms, vitamins, and / or minor elements. When probiotics are used, they may be included in a live form, semi-active or de-active form, such as a lyophilized powder. A culture supernatant of the microorganism may also be included in the composition. They may be selected from the group consisting of lactic acid bacteria, in particular lactobacilli and / or bifidobacteria, preferably Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus casei, Bifidobactedum bifidum, Bifidobacterium breve, Bifidobacterium breve, Bifidobacterium breve, Selected from the group consisting of Bifidobacterium dolescentis and Bifidobacterium pseudocatenulatum. In the most preferred embodiment, the strain used is Lactobacillus johnsonii (La1) deposited on June 30, 1992 under the Budapest Treaty and receiving deposit number CNCM I-1225, or Lactobacillus paracasei (ST11) deposited at the Tool Association under the Budapest Treaty on January 12, 1999 and receiving the deposit number CNCM I-2116. For example, the following compounds: zinc and its salts including zinc sulfate and zinc glucanate, vitamins B5, B6, B8, C, E or PP, β-carotene and carotenoids, extracts of garlic, especially allyl sulfide or garlic oil Selenium, curcumin, curcuminoids, niacin, purple root acid, and adenosine may be used alone or in combination. The expert will select such active compounds and, if possible, prevent the desired activity of interest from being inhibited or diminished by reducing the composition that is the object of the present invention. It is understood that they will be combined in a way that improves the expected effect.
Compositions intended for oral administration comprise 0.1% to 80% decaffeinated coffee bean extract, preferably 1% to 50% based on the weight of the composition. It is contained in an amount in the range of.
あるコーヒー豆の抽出物に天然に存在しているフェノール化合物であるクロロゲン酸は、乾燥肌の処置に関与していない。
よって、クロロゲン酸は、本発明の乾燥肌を処置及び/又は防止する組成物の活性剤ではない。従って、特定の実施態様では、クロロゲン酸は組成物の重量に対して0.1%以下の量で、脱カフェインされたコーヒー豆を含有する組成物に存在している。
Chlorogenic acid, a phenolic compound naturally present in certain coffee bean extracts, is not involved in the treatment of dry skin.
Thus, chlorogenic acid is not an active agent in the composition for treating and / or preventing dry skin of the present invention. Accordingly, in certain embodiments, chlorogenic acid is present in a composition containing decaffeinated coffee beans in an amount of 0.1% or less based on the weight of the composition.
また本発明は、上述したようなコーヒー豆の抽出物を含有する組成物を、経口経路により投与することからなる、皮膚加齢の防止及び/又は美容処理のための方法、又は乾燥肌の防止及び/又は処置のための美容方法に関する。
乾燥肌の処置のため、経口経路で投与される脱カフェインされたコーヒー豆の抽出物の毎日の投与量は、好ましくは0.01〜5000mg/日が含まれる。優先的には、コーヒー豆の抽出物は、0.5〜1000mg/日からなる投与量で、それを投与可能な量として、本発明の組成物に存在している。
上述した本発明の特徴等は、以下に記載する実施例に照らせば、さらに明らかになるであろう。
Further, the present invention provides a method for preventing skin aging and / or cosmetic treatment, or preventing dry skin, comprising administering a composition containing a coffee bean extract as described above by the oral route. And / or a cosmetic method for treatment.
For the treatment of dry skin, the daily dose of decaffeinated coffee bean extract administered by the oral route preferably comprises 0.01 to 5000 mg / day. Preferentially, the coffee bean extract is present in the composition of the present invention at a dose comprised between 0.5 and 1000 mg / day as an administrable amount.
The above-described features and the like of the present invention will become more apparent in light of the embodiments described below.
実施例1:コフィア属ロブスタ種の焙煎した抽出物の調製
0.5kgの焙煎したコーヒー豆を、4℃で1分間(氷浴)、24000回転/分のTurrax装置を用いて粉砕することにより、パウダーになるまで小さくする。
得られたパウダーをpH8.5の0.05Mリン酸緩衝液5リットルと混合する。全混合物を4℃で30分攪拌し、ついで、4℃で10000Gの遠心分離にかける。上清を、0.22μmフィルターを通して濾過する(滅菌濾過)。
ついで、酸化現象を取り除くため、縫工型(Sartorius)膜を通して限外濾過することにより、抽出物を分画する。
ついで、抽出物を凍結乾燥させる。このようにして、「凍結乾燥抽出物」と称される29.5グラムの活性抽出物が得られる。
次に、超臨界クロマトグラフィー(キャリアガスとしてCO2を使用)により、カフェインを除去する。このようにして、「脱カフェインされた凍結乾燥抽出物」と称される、25.5グラムの活性抽出物が得られる。
Example 1: Preparation of a roasted extract of Kofia robusta seed 0.5 kg of roasted coffee beans is ground using a Turrax apparatus at 24,000 rpm for 1 minute at 4 ° C (ice bath) To reduce to powder.
The resulting powder is mixed with 5 liters of 0.05M phosphate buffer at pH 8.5. The whole mixture is stirred for 30 minutes at 4 ° C. and then centrifuged at 10000 G at 4 ° C. The supernatant is filtered through a 0.22 μm filter (sterile filtration).
The extract is then fractionated by ultrafiltration through a Sartorius membrane to remove oxidation phenomena.
The extract is then lyophilized. In this way, 29.5 grams of active extract referred to as “lyophilized extract” is obtained.
Next, caffeine is removed by supercritical chromatography (using CO 2 as a carrier gas). In this way, 25.5 grams of active extract, referred to as “decaffeinated lyophilized extract”, is obtained.
実施例2:本発明、特に本発明の組成物の例証のための処方例
これらの組成物は、種々の成分を単に混合することにより得られた。
組成物1:ソフトカプセル
割形剤:
大豆油 40mg
小麦胚芽油 85mg
大豆レシチン類 25mg
ビタミン類:
天然のトコフェロール類 3mg
ビタミンCパルミテート 150mg
成分:
コフィア属ロブスタ種の脱カフェインされた
凍結乾燥抽出物 15mg
ルリヂサ油 200mg
クロフサスグリの種油 150mg
Example 2: Formulation Examples for Illustrating the Invention, In particular the Compositions of the Invention These compositions were obtained by simply mixing the various ingredients.
Composition 1: Soft capsule splitting agent:
Soybean oil 40mg
Wheat germ oil 85mg
Soybean lecithin 25mg
Vitamins:
Natural tocopherols 3mg
Vitamin C palmitate 150mg
component:
15 mg of decaffeinated lyophilized extract of Kofia robusta
Borage oil 200mg
Black currant seed oil 150mg
組成物2:ソフトカプセル
割形剤:
大豆油 40mg
小麦胚芽油 85mg
大豆レシチン類 25mg
ビタミン類:
天然のトコフェロール類 3mg
成分:
コフィア属ロブスタ種の脱カフェインされた
凍結乾燥抽出物 150mg
ルリヂサ油 200mg
月見草油 200mg
Composition 2: Soft capsule splitting agent:
Soybean oil 40mg
Wheat germ oil 85mg
Soybean lecithin 25mg
Vitamins:
Natural tocopherols 3mg
component:
150 mg of decaffeinated lyophilized extract of Kofia robusta
Borage oil 200mg
Evening primrose oil 200mg
組成物3:ソフトカプセル
割形剤:
大豆油 40mg
小麦胚芽油 85mg
大豆レシチン類 25mg
ビタミン類:
天然のトコフェロール類 3mg
成分:
コフィア属ロブスタ種の脱カフェインされた
凍結乾燥抽出物 50mg
ルリヂサ油 200mg
月見草油 200mg
凍結乾燥された乳酸桿菌 200mg
Composition 3: Soft capsule splitting agent:
Soybean oil 40mg
Wheat germ oil 85mg
Soybean lecithin 25mg
Vitamins:
Natural tocopherols 3mg
component:
50 mg of decaffeinated lyophilized extract of Kofia robusta
Borage oil 200mg
Evening primrose oil 200mg
Freeze-dried lactobacilli 200mg
組成物4:ソフトカプセル
割形剤:
大豆油 40mg
小麦胚芽油 5mg
大豆レシチン類 25mg
ビタミン類:
天然のトコフェロール類 3mg
成分:
コフィア属ロブスタ種の脱カフェインされた
凍結乾燥抽出物 150mg
ルリヂサ油 200mg
月見草油 200mg
ビタミンC 50mg
グルカン酸カルシウム 200mg
ステアリン酸マグネシウム 400mg
凍結乾燥された乳酸桿菌種 300mg
Composition 4: Soft capsule splitting agent:
Soybean oil 40mg
Wheat germ oil 5mg
Soybean lecithin 25mg
Vitamins:
Natural tocopherols 3mg
component:
150 mg of decaffeinated lyophilized extract of Kofia robusta
Borage oil 200mg
Evening primrose oil 200mg
Vitamin C 50mg
Calcium glucanate 200mg
Magnesium stearate 400mg
300 mg of lyophilized Lactobacillus species
Claims (12)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0215867A FR2848448B1 (en) | 2002-12-13 | 2002-12-13 | USE OF DECAFFEIN COFFEE GRAIN EXTRACT IN THE PREPARATION OF A COMPOSITION FOR STIMULATING THE SEBACEOUS FUNCTION OF THE SKIN BY ORAL ADMINISTRATION |
PCT/EP2003/015026 WO2004054535A1 (en) | 2002-12-13 | 2003-12-12 | Use of an extract of decaffeinated coffee beans in the preparation of a composition intended to stimulate the sebaceous function of the skin by oral administration |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2006511603A true JP2006511603A (en) | 2006-04-06 |
Family
ID=32338797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005502448A Pending JP2006511603A (en) | 2002-12-13 | 2003-12-12 | Use of decaffeinated coffee bean extract in the preparation of compositions intended to stimulate the sebaceous gland function of the skin by oral administration |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2006511603A (en) |
CN (1) | CN1726007A (en) |
FR (1) | FR2848448B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013533282A (en) * | 2010-07-30 | 2013-08-22 | ネステク ソシエテ アノニム | Use of non-roasted coffee beans to regulate skin pigmentation diseases |
JP2013535461A (en) * | 2010-07-30 | 2013-09-12 | ネステク ソシエテ アノニム | Use of roasted coffee beans to regulate skin pigmentation |
JP2013537528A (en) * | 2010-07-30 | 2013-10-03 | ネステク ソシエテ アノニム | Use of a mixture of roasted and non-roasted coffee beans to control skin pigmentation |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2872047B1 (en) * | 2004-06-23 | 2007-06-15 | Oreal | COMPOSITION FOR SENSITIVE SKINS COMBINING MINERAL AND PROBIOTIC CATION (S) |
MXPA06015184A (en) * | 2004-06-23 | 2007-11-22 | Nestec Sa | Method and compositions useful for preventing and/or treating sensitive and/or dry skin. |
CN1879727B (en) * | 2006-05-09 | 2010-04-21 | 中国科学院上海药物研究所 | Novel hepatitis B inhibitor and application thereof |
FR2920305B1 (en) | 2007-09-04 | 2010-07-30 | Oreal | USE OF A SPECIFIC BIFIDOBACTERIUM LYSATE FOR THE TREATMENT OF SENSITIVE SKINS. |
FR2920304B1 (en) | 2007-09-04 | 2010-06-25 | Oreal | COSMETIC USE OF LYSAT BIFIDOBACTERIUM SPECIES FOR THE TREATMENT OF DROUGHT. |
FR2942719B1 (en) | 2009-03-04 | 2011-08-19 | Oreal | USE OF PROBIOTIC MICROORGANISMS TO LIMIT SKIN IRRITATION |
CN103616426B (en) * | 2013-12-02 | 2016-05-11 | 中国科学院上海应用物理研究所 | A kind of micro-fluidic electrochemica biological sensor-based system and using method thereof of the integrated form for quick biochemical analysis |
FR3030253B1 (en) * | 2014-12-18 | 2018-03-02 | Nutricos Technologies | COMPOSITION FOR IMPROVING THE CELLULAR ASPECT OF THE SKIN |
CN111616995A (en) * | 2020-04-14 | 2020-09-04 | 云南英格生物技术有限公司 | Coffee silverskin extract and preparation method and application thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1533371A (en) * | 1967-06-07 | 1968-07-19 | Dermo-cosmetic products based on coffee tree extracts | |
US3660107A (en) * | 1970-01-23 | 1972-05-02 | Meyer Lab Inc | Effervescent beverage powder and tableted beverage compositions |
DE3920209A1 (en) * | 1989-06-21 | 1991-03-28 | Nolde Sylvia | Caffeine free coffee sweets - made from decaffeinated coffee, milk prods., sugar, sweeteners, flavourings, etc. |
EP0534024B1 (en) * | 1991-09-23 | 1995-04-19 | Kraft Foods, Inc. | Decaffeinated coffee products with reduced potassium content |
EP0582147A3 (en) * | 1992-08-03 | 1994-08-24 | Nestle Sa | Anti-urease cosmetic or dermatologic composition |
IT1290806B1 (en) * | 1997-03-21 | 1998-12-11 | Universal Flavors S R L | DECAFFEINATED EXTRACTS FROM MATE ' |
US20020160067A1 (en) * | 2001-04-25 | 2002-10-31 | Oncology Science Corporation | Therapeutic preparation and method for producing a therapeutic preparation using coffee beans as a substrate |
-
2002
- 2002-12-13 FR FR0215867A patent/FR2848448B1/en not_active Expired - Fee Related
-
2003
- 2003-12-12 CN CNA2003801059661A patent/CN1726007A/en active Pending
- 2003-12-12 JP JP2005502448A patent/JP2006511603A/en active Pending
Non-Patent Citations (3)
Title |
---|
JPN6010010388, TSE,S.Y., "Coffee contains cholinomimetic compound distinct from caffeine. I: Purification and chromatographic", J Pharm Sci, 1991, Vol.80, No.7, p.665−9 * |
JPN6010010389, "Cholinomimetic compound distinct from caffeine contained in coffee. II: Muscarinic actions", J Pharm Sci, 1992, Vol.81, No.5, p.449−52 * |
JPN6010010390, CARTLIDGE,M. et al, "The effect of prolonged topical application of an anticholinergic agent on the sebaceous glands", Br J Dermatol, 1972, Vol.86, No.1, p.61−3 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013533282A (en) * | 2010-07-30 | 2013-08-22 | ネステク ソシエテ アノニム | Use of non-roasted coffee beans to regulate skin pigmentation diseases |
JP2013535461A (en) * | 2010-07-30 | 2013-09-12 | ネステク ソシエテ アノニム | Use of roasted coffee beans to regulate skin pigmentation |
JP2013537528A (en) * | 2010-07-30 | 2013-10-03 | ネステク ソシエテ アノニム | Use of a mixture of roasted and non-roasted coffee beans to control skin pigmentation |
Also Published As
Publication number | Publication date |
---|---|
FR2848448B1 (en) | 2007-04-06 |
FR2848448A1 (en) | 2004-06-18 |
CN1726007A (en) | 2006-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060018986A1 (en) | Extracts of decaffeinated coffee beans and orally administrable compositions comprised thereof for stimulating the sebaceous function of the skin | |
EP2285343B1 (en) | Use of a wolfberry extract, for maintaining and/or restoring the tonus and/or firmness of the skin | |
EP2598103B1 (en) | Use of roasted coffee beans for regulating skin pigmentation | |
WO2009141544A2 (en) | Use of a berry extract, especially a wolfberry extract, for treating dryness of keratin materials | |
JP2013512947A (en) | Probiotic microorganisms as active agents against changes in the microrelief of the skin | |
JP2009263275A (en) | Antioxidant and cosmetic product, food and drink composition and pharmaceutical composition containing the same | |
JP2013533282A (en) | Use of non-roasted coffee beans to regulate skin pigmentation diseases | |
JP2006511603A (en) | Use of decaffeinated coffee bean extract in the preparation of compositions intended to stimulate the sebaceous gland function of the skin by oral administration | |
CN103068360B (en) | The mixture of roast coffee beans and raw coffee bean is used for the Pigmented purposes of regulation of skin | |
WO2009141543A1 (en) | Use of a berry extract, especially a wolfberry extract, as an anti-pollutant | |
FR2942720A1 (en) | Use of hesperidin or one of its derivatives to stimulate epidermal cell renewal process of keratin material before undergoing a consecutive surface skin treatment or invasive treatment from Wrinkle-Filler Injection for aesthetic purpose | |
JP6909569B2 (en) | Skin quality improver | |
KR20140073835A (en) | Cosmetic composition comprising of Salicornia herbacea extracts for inhibiting secretion of sebum | |
JP2008106029A (en) | Hyperoxidation inhibitor for lipid in living body | |
KR20160043698A (en) | Composition for treating hair or scalp to prevent hair loss | |
JP2012051938A (en) | Composition for lustrous skin | |
JP2021045052A (en) | Lipin-1 gene expression enhancer | |
FR2943248A1 (en) | Cosmetic use of extract of wolfberry as agent for preventing and/or treating scalp disorders, preferably dandruff condition of scalp | |
FR2967064A1 (en) | Non-therapeutic cosmetic use of at least one pomegranate extract, as agent for preventing and/or treating heavy legs, swollen ankles, aching legs, and varicose veins, and in food supplement e.g. food bars, mineral water and soups |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061004 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100323 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100831 |